ASCO Trending: GeparNuevo
24.08.2018
Priming the Immune System: Neoadjuvant Durvalumab Plus Chemotherapy May Be Beneficial in Triple-Negative Breast Cancer
The addition of durvalumab to anthracycline/taxane-based chemotherapy had encouraging results as neoadjuvant therapy for early triple-negative breast cancer in the randomized phase II GeparNuevo study presented by Sibylle Loibl, MD, PhD, at the 2018 ASCO Annual Meeting. The results were positive in a subgroup of patients who received durvalumab alone during a 2-week “window of opportunity” to prime the immune system prior to receiving chemotherapy.
News
-
21.09.2023 New review on Immune Cell Infiltration published
A review from the International Immuno-Oncology Biomarker Working about tumor immunology was published in the journal of pathology.
Mehr ... -
07.09.2023 Save the date! GBG Annual Scientific Meeting 2024
Das 21. Annual Scientific Meeting 2024 wird am 29.2. bis 1.3. in Frankfurt stattfinden.
Mehr ... -
05.05.2023 GBG Research at ESMO-BC 2023
GBG Research at ESMO-Breast Cancer Conference 2023 in Berlin
Mehr ... -
28.02.2023 Annual Scientific Report 2022 published
Our Annual Scientific Report 2022 provides a concise overview of current study findings along with important lectures and research posters presented by our members from the last year.
Mehr ... -
24.01.2023 Save the date: 20th GBG Annual Meeting 2023
The 20th GBG Annual Meeting 2023 will start 2nd to 3rd of March 2023 at the Steigenberger Airport Hotel
Mehr ...